Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Up 317.1% in April

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 105,100 shares, a growth of 317.1% from the March 31st total of 25,200 shares. Based on an average daily volume of 497,100 shares, the short-interest ratio is currently 0.2 days. Approximately 25.0% of the shares of the company are sold short.

Allarity Therapeutics Stock Performance

NASDAQ:ALLR traded up $0.06 during mid-day trading on Thursday, hitting $1.43. 221,894 shares of the company traded hands, compared to its average volume of 407,973. The stock’s fifty day moving average price is $5.84 and its 200-day moving average price is $8.94. Allarity Therapeutics has a one year low of $1.27 and a one year high of $415.92.

Institutional Trading of Allarity Therapeutics

An institutional investor recently bought a new position in Allarity Therapeutics stock. Sabby Management LLC purchased a new stake in shares of Allarity Therapeutics, Inc. (NASDAQ:ALLR) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 359,400 shares of the company’s stock, valued at approximately $268,000. Allarity Therapeutics accounts for approximately 0.2% of Sabby Management LLC’s investment portfolio, making the stock its 21st largest position. Sabby Management LLC owned 13.16% of Allarity Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 11.53% of the company’s stock.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.